welcome to cyprotexcloe® screencloe® selectcloe® predict
home > investor relations

Highlights

Final Results to 31 December 2009

  • Revenues hit £5 million for second successive year at £5.00 million (2008: £5.18 million)
  • Second year of profitability with operating profits at £0.46 million (2008: £0.57 million)
  • Cash and cash equivalents up £0.49 million at £2.07 million
  • Strong positive cash flow from operations at £0.90 million up £0.36 million

Commenting on the results, Steve Harris, Chairman of Cyprotex PLC, said:

"Cyprotex's results represent an impressive performance against a very difficult market currently for the pre-clinical CRO sector. Cyprotex continues to attract new customers, expand its offerings and is investing in new laboratories to service both the ADME and pre-clinical toxicology markets"

Download Final Results to 31 December 2009

contact

Find out more about us.

Investor Relations
Anthony Baxter/Mark Warburton

Call on +44 1625 505100

contact
careerscontactlegalprivacy
This website was last updated
on 29th July 2010
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.